Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Realgar-Indigo naturalis formula plus VRD for newly diagnosed multiple myeloma
ChiCTR1900023193Phase 4Not yet recruiting
- Sponsor
- Huadong Hospital, Fudan University
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Compound Huangdai Tablet, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Huadong Hospital, Fudan University. Primary endpoint: M protein. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
Compound Huangdai Tabletbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR1900023193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023193.